http://web.archive.org/web/20110131011715id_/http://edition.cnn.com/2009/HEALTH/02/25/fda.india.generic.drugs/index.html

@entity0 -- the @entity2 said wednesday that it has stopped reviewing drug applications from an @entity5 - based pharmaceutical plant , alleging that officials there falsified data and test results in applications , some of which the agency has already approved			1
in its second action in six months against @entity17 's @entity16 plant , the @entity2 invoked its @entity18 , which is usually invoked over concerns about the integrity of data in drug applications			1
in september , the @entity2 issued an import alert barring entry of generic drugs produced at the plant in northeastern @entity5 and two others owned by @entity17			1
that order remains in effect			0
a man who answered the phone at the company 's offices in @entity34 , @entity35 , @entity5 , said no one was available for comment			2
no one immediately answered an e-mail sent wednesday to the company 's @entity41 corporate offices in @entity43 , @entity44			2
under the @entity18 , the most recent action , the @entity2 has stopped all scientific review of any new or pending drug approval applications containing data from the @entity16 plant			2
in a letter sent wednesday to the company , the agency alleged that data submitted from the @entity17 plant contained falsified information -- including lies that safety tests were conducted , lies that drugs had been kept at room temperature when in fact they had been stored in refrigerators , and lies about the shelf life of some drugs			1
" companies must provide truthful and accurate information in their marketing applications , " said dr. @entity63 , director of the @entity2 's @entity64 , in a statement on the @entity2 web site			2
" the @entity41 public expects and deserves no less			0
" an investigation is under way , but the @entity2 said it has no evidence that drugs manufactured at the plant do not meet quality specifications			2
in a written statement e-mailed to @entity1 , a spokesperson said the company had just been notified of the action			0
" @entity17 will analyze the letter and other information fully and respond appropriately in a timely manner , " it said			0
" the @entity2 has said it has no evidence the drugs on the market are substandard and also that they comply with specifications upon testing , " it added			0
@entity91 , director of the drug evaluation center 's @entity92 , said there is no reason to believe @entity17 drugs on @entity41 shelves pose any safety threat			1
she said all 80 samples tested met application specifications			0
" we feel comfortable leaving those products on the @entity41 market at this time , " she said			0
the @entity2 said it has approved some 25 drug applications that contain data from @entity16			1
the applications affected by wednesday 's announcement are for approved drugs made for the @entity41 market , drugs pending approval but not yet on the market , and certain drugs manufactured in @entity17 's @entity112 in @entity44 , which relied on data from the @entity16 plant			1
three generic drugs were produced at @entity112 : simvastatin ( @entity116 ) and pravastatin ( @entity118 ) , both cholesterol - lowering drugs called statins , and the antihistamine loratadine ( @entity119 )			0
the four plants in @entity5 that make drugs approved for distribution in the @entity41 have been inspected more than 20 times since 2005 , the @entity2 said			1
the @entity2 advised patients to talk with their doctor before considering stopping any medications .			0

@entity2 stops drug applications from @entity5 - based drug plant
plant officials falsified data on applications , agency says
official : no reason to believe company 's drugs on @entity41 shelves pose any safety threat

@entity17:Ranbaxy
@entity2:FDA
@entity1:CNN
@entity0:WASHINGTON
@entity35:Haryana
@entity34:Gurgaon
@entity5:India
@entity16:Paonta Sahib
@entity112:Ohm Laboratories
@entity18:Application Integrity Policy
@entity44:New Jersey
@entity116:Zocor
@entity91:Deborah Autor
@entity41:U.S.
@entity43:Princeton
@entity63:Janet Woodcock
@entity64:Center for Drug Evaluation and Research
@entity92:Office of Compliance
@entity119:Claritin
@entity118:Pravachol